MARKET

STTK

STTK

Shattuck Labs, Inc.
NASDAQ
4.640
+0.170
+3.80%
After Hours: 4.640 0 0.00% 17:16 01/16 EST
OPEN
4.470
PREV CLOSE
4.470
HIGH
4.680
LOW
4.360
VOLUME
485.60K
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
0.6922
MARKET CAP
293.62M
P/E (TTM)
-4.5499
1D
5D
1M
3M
1Y
5Y
1D
Shattuck Labs: "Hold" On Oncology Exit And Competitive TL1A/DR3 Pathway Pivot
Seeking Alpha · 1d ago
Shattuck Labs Files Shelf Registration To Offer Up To $200M Of Common Stock, Preferred Stock, Debt, Warrants And Units
Benzinga · 4d ago
Shattuck Labs files $200M mixed securities shelf
TipRanks · 4d ago
SHATTUCK LABS INC - MAY ISSUE UP TO $200 MLN IN SECURITIES - SEC FILING
Reuters · 4d ago
Weekly Report: what happened at STTK last week (0105-0109)?
Weekly Report · 5d ago
Earnings Season To Kick Off As Banking Heavyweights Report, Inflation Data In Focus
Seeking Alpha · 01/10 16:00
Catalyst Watch: Big bank earnings, major healthcare + retail conferences, Fedspeak flurry, CPI
Seeking Alpha · 01/09 20:00
Shattuck Labs Is Maintained at Neutral by Citigroup
Dow Jones · 01/06 18:50
More
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Webull offers Shattuck Labs Inc stock information, including NASDAQ: STTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STTK stock methods without spending real money on the virtual paper trading platform.